March 22, 2019
Updated 1mo ago
Biogen stock has plummeted more than 30% after the biotech company announced it was cancelling its trial for a drug that would hopefully help treat Alzheimer's. An independent audit found that the drug was unlikely to work. Salim Syed, Senior Biotechnology Analyst at Mizuho, joined Cheddar Business to discuss his expectations for the company's future.